查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529867

生物標記測試服務市場規模、佔有率、趨勢分析報告：按服務、按類型、按最終用途、按地區、細分市場預測，2024-2030 年

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Type (Molecular Biomarkers, Cellular Biomarkers), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

生物標記測試服務市場成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，預計到 2030 年，全球生物標記檢測服務市場規模將達到 10.565 億美元，2024 年至 2030 年複合年成長率為 8.46%。

藥物研發投資的增加、癌症治療中對精準醫學的需求增加、感染疾病和慢性疾病負擔的增加推動了生物標記測試的需求，這些是推動市場成長的主要因素。

過去五年來，臨床試驗持續增加。例如，根據ClinicalTrials.gov的數據，2018年註冊的臨床試驗超過262,298項，截至2022年9月，註冊的臨床試驗超過399,518項。由於臨床研究資金的增加，預計未來幾年臨床試驗將會改善。預計這將增加對藥物發現研究活動的需求，並支持大流行後時期對生物標記測試的需求。

FDA對使用生物標記的藥物的核准率逐年上升。例如，2016年，超過26項使用生物標記進行醫學測試的臨床試驗獲得FDA核准，2019年，FDA核准了36項使用生物標記進行醫學測試的臨床試驗。臨床試驗現在需要生物標記相關資料來進行藥物核准，因為它們提供了有關藥物如何在體內發揮作用的資訊，從而加快了藥物核准過程。因此，預計在預測期內對生物標記測試的需求將會增加。

各種生物製藥公司正在努力透過生物標記測試來提高癌症患者的診斷率。例如，2021年4月，生物製藥公司安進推出了生物標記輔助計畫。根據該計劃，為轉移性（IV 期）非小細胞肺癌（NSCLC）患者提供生物標記測試，以確認是否存在有助於標靶治療的癌症基因生物標記。市場參與企業的這些舉措預計將支持市場成長。

根據 IQVIA 的腫瘤學趨勢報告，癌症臨床試驗在過去十年中持續增加。例如，2011年註冊了1,242項臨床試驗，截至2021年，已註冊2,335項臨床試驗。由於盛行率不斷增加，針對癌症的臨床試驗數量預計將進一步增加。使用生物標記來測試研究中藥物有效性的標靶治療的需求不斷增加。未來幾年癌症研究的增加預計將推動對用於癌症檢測的生物標記的需求，從而支持大流行後時期的市場。

生物標記測試服務市場報告亮點

  • 按服務分類的生物標記檢測開發和檢驗領域預計到 2023 年將佔據最大佔有率，達到 45.61%。疾病診斷中對伴同性診斷的需求不斷成長，預計將支持對生物標記檢測開發和驗證服務的需求。
  • 依最終用途分類，製藥和生技公司佔最大佔有率，2023年將達45.7%。
  • 北美地區佔比最大，2023年為46.2%。技術先進的研究基礎設施和公共機構不斷增加的研究投資正在支持該地區的市場成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章生物標記測試服務市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
  • 生物標記測試服務市場：分析工具
  • COVID-19 影響分析

第 4 章 生物標記檢測服務市場：按服務分類的估計和趨勢分析

  • 細分儀表板
  • 全球生物標記檢測服務市場波動分析
  • 2018-2030年全球生物標記檢測服務市場規模及趨勢分析（按服務）
  • 生物標記測定的開發和檢驗
  • 流式細胞技術
  • 其他

第5章生物標記檢測服務市場：按類型估計和趨勢分析

  • 細分儀表板
  • 全球生物標記檢測服務市場波動分析
  • 2018-2030年全球生物標記檢測服務市場規模及趨勢分析（按類型）
  • 分子生物標記
  • 細胞生物標記

第6章 生物標記檢測服務市場：依最終用途分類的估計與趨勢分析

  • 細分儀表板
  • 全球生物標記檢測服務市場波動分析
  • 2018-2030 年全球生物標記測試服務市場規模和趨勢分析（按最終用途）
  • 製藥和生物技術公司
  • 研究所
  • CRO

第7章生物標記檢測服務市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 2018 年至 2030 年市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018 年至 2030 年市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018 年至 2030 年市場估計與預測
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 印尼
    • 馬來西亞
    • 新加坡
    • 台灣
  • 拉丁美洲
    • 2018 年至 2030 年市場估計與預測
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東/非洲
    • 2018 年至 2030 年市場估計與預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 以色列

第8章 競爭格局

  • 市場參與企業分類
    • 市場領導
    • 新興玩家
  • 服務熱圖分析（公司比較分析）
  • 公司簡介
    • Bio Agilytix Labs
    • Eurofins Scientific
    • SGS SA.
    • Charles River Laboratories
    • LabCorp
    • Thermo Fisher Scientific Inc.（PPD, Inc.）
    • ICON Plc
    • IQVIA
    • Syneos Health
    • Intertek Group Plc
Product Code: GVR-4-68039-986-1

Biomarker Testing Services Market Growth & Trends:

The global biomarker testing services market size is expected to reach USD 1,056.5 million by 2030, registering a CAGR of 8.46% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights:

  • The biomarker assay development & validation segment by service was expected to hold the largest share of 45.61% in 2023. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
  • Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 45.7% in 2023, owing to the rising investment in R&D by these companies
  • North America held the largest share of 46.2% in 2023, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definition
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Detail
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives
    • 1.9.1. Objective - 1:
    • 1.9.2. Objective - 2:
    • 1.9.3. Objective - 3:
    • 1.9.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service Outlook
    • 2.2.2. Type Outlook
    • 2.2.3. End-Use Outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for Biomarker Testing for Cancer Detection
      • 3.2.1.2. Increasing R&D Activities
      • 3.2.1.3. Growing Burden of Chronic and Infectious Diseases Supporting Demand for Biomarker Testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Capital Investments and Lengthy Timelines for Biomarker Development
  • 3.3. Biomarker Testing Services Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. Biomarker Testing Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biomarker Testing Service Market Movement Analysis
  • 4.3. Global Biomarker Testing Service Market Size & Trend Analysis, by services, 2018 to 2030 (USD Million)
  • 4.4. Biomarker Assay Development & Validation
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Flow Cytometry
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Testing Services Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biomarker Testing Services Market Movement Analysis
  • 5.3. Global Biomarker Testing Services Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Molecular Biomarkers
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Cellular Biomarkers
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Testing Services Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biomarker Testing Services Market Movement Analysis
  • 6.3. Global Biomarker Testing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical and Biotechnology Companies
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Research Institutes
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. CROs
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biomarker Testing Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Scenario
      • 7.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.8. Indonesia
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Scenario
      • 7.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.9. Malaysia
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Competitive Scenario
      • 7.6.9.3. Regulatory Scenario
      • 7.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.10. Singapore
      • 7.6.10.1. Key Country Dynamics
      • 7.6.10.2. Competitive Scenario
      • 7.6.10.3. Regulatory Scenario
      • 7.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.11. Taiwan
      • 7.6.11.1. Key Country Dynamics
      • 7.6.11.2. Competitive Scenario
      • 7.6.11.3. Regulatory Scenario
      • 7.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.4. Colombia
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.6. Israel
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Scenario
      • 7.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 8.3. Company Profiles
    • 8.3.1. Bio Agilytix Labs
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Eurofins Scientific
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. SGS SA.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Charles River Laboratories
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. LabCorp
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Thermo Fisher Scientific Inc. (PPD, Inc.)
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. ICON Plc
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. IQVIA
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Syneos Health
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Intertek Group Plc
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List oList of Tables
  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 4. Global Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 5. Global Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 6. Global Biomarker Testing Services, by Region, 2018 - 2030 (USD Million)
  • Table 7. North America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 8. North America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 9. North America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 10. North America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 11. U.S. Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 12. U.S. Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 13. U.S. Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 14. Canada Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 15. Canada Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 16. Canada Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 17. Mexico Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 18. Mexico Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 19. Mexico Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 20. Europe Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 21. Europe Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 22. Europe Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 23. Europe Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 24. Germany Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 25. Germany Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 26. Germany Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 27. UK Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 28. UK Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 29. UK Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 30. France Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 31. France Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 32. France Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 33. Italy Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 34. Italy Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 35. Italy Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 36. Spain Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 37. Spain Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 38. Spain Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 39. Denmark Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 40. Denmark Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 41. Denmark Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 42. Sweden Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 43. Sweden Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 44. Sweden Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 45. Norway Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 46. Norway Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 47. Norway Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 52. China Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 53. China Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 54. China Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 55. Japan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 56. Japan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 57. Japan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 58. India Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 59. India Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 60. India Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 61. South Korea Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 62. South Korea Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 63. South Korea Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 64. Australia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 65. Australia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 66. Australia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 67. Thailand Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 68. Thailand Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 69. Thailand Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 70. Indonesia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 71. Indonesia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 72. Indonesia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 73. Malaysia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 74. Malaysia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 75. Malaysia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 76. Singapore Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 77. Singapore Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 78. Singapore Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 79. Taiwan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 80. Taiwan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 81. Taiwan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 82. Latin America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 83. Latin America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 84. Latin America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 85. Latin America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 86. Brazil Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 87. Brazil Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 88. Brazil Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 89. Argentina Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 90. Argentina Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 91. Argentina Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 92. Middle East & Africa Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 93. Middle East & Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 94. Middle East & Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 95. Middle East & Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 96. South Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 97. South Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 98. South Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 99. Saudi Arabia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 100. Saudi Arabia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 101. Saudi Arabia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 102. UAE Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 103. UAE Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 104. UAE Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 105. Kuwait Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 106. Kuwait Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 107. Kuwait Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 108. Israel Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 109. Israel Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 110. Israel Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biomarker Testing Services, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biomarker Testing Services, for Biomarker Assay Development & Validation, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biomarker Testing Services, for Flow Cytometry, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biomarker Testing Services, for Molecular Biomarkers, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biomarker Testing Services, for Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biomarker Testing Services, for CROs, 2018 - 2030 (USD Million)
  • Fig. 18 Regional Outlook, 2023 & 2030
  • Fig. 19 North America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Canada Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Mexico Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Europe Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Germany Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 UK Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 France Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Italy Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Spain Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Denmark Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sweden Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Norway Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Asia Pacific Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Japan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 China Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 India Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Australia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 South Korea Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Thailand Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Indonesia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Malaysia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Singapore Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Taiwan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Israel Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)